When An SPA Is Not Enough: FDA Will Consider Response Rate For Allos Drug

The trial supporting the NDA for Allos Therapeutics' peripheral T-cell lymphoma drug pralatrexate was conducted under a Special Protocol Assessment with FDA - but that does not necessarily mean the magnitude of benefit shown will satisfy the agency